Bad week for us last week, down 3.3%. LTUS keeps dragging us down with another double digit decline (19%) and SuperGen dropped 10% on what we think is good news-long term.
AVSO, SUPG, EXTR, and LTUS.ob are our favorites.
The DOW was even last week, NASDAQ was down .3% and the S+P 500 was down .3%. The Russell 3000 and the Wilshire 5000 were both down about .4%.
For the year so far, we are up 3.3%. The DOW is up 6.9%, NASDAQ is up 4.8%, S+P 500 is up 5.6%, the Russell 3000 is up 6.0% and the Wilshire is up 5.8%.
Last week we went 6 stocks up, 10 down and 2 even. Since inception we are now 51 stocks up and 12 down for a 81% winning percentage (80% is our target win %).
Since our beginning, we have closed out the following positions:
2006-ONXS +11% (Buyout offer)
2006-CAW +21% (Buyout offer)
2007-IYXI.ob +44% (Buyout offer)
2007-MOBI +47% (Buyout offer)
2007-INFT +11% (Buyout offer)
2007-DTLK +25% (2 weeks)
2007-PDLI + 3%
2007-LINN.ob -57% (mortgage business bust didn’t help here)
2007-TISA -39% (take some tax loss for 2007 due to disappointing results.
2008-OPTO.ob +40% (Buy-out offer)
2008-PDLI +9% (company split, and special dividend)
2008-BDAY -39% (long overdue takeover offer-or “take-under”)
2008-DTLK +40% (third trip on this one)
2008-ILOG +26% (Buy-out offer from IBM)
2009-HSTM +67% (continued good earnings)
2009-CLZR -32% (a loser even on a buy-out)
2009-DTLK +28% (our 5th profitable trip on this one)
2010-CHRD +37% Buyout (2 weeks after we recommended it)
2010-CAW EVEN (excluding 2.5 years of dividends)
The model portfolio assumes $10,000 invested in each stock (unless we double-up–then it is $20,000), less $10 commission each way (TD Ameritrade rate).
For the 45 stocks that we closed out since 2006 (41 were winners) the average net gain was 33%.
Rosetta Stone Inc. (NYSE-RST)-Recommended 3/3/2011)
Closed up $.63 at $14.05
Harris Interactive (NASDAQ-HPOL)-Recommended 3/3/2010)
Closed at $1.05, up $.08
Concurrent Computer (NASDAQ-CCUR)-Recommended 2/4/2011)
Closed down $.04 at $6.02
Last week the ompany announed that it would not do the stock buy back that Skellig was suggesting. We don’t like buy backs anyway. Hopefully Skellig will keep pushing management to get the share price up.
Skellig Capital Management filed a 13D/A in March suggesting that CCUR use their excess cash to do a share buy back. They used examples in the filing of $6.60 and $6.90 a share. They also bought a few more shares of CCUR. Their ownership is up to 5.86%.
SuperGen Inc. (NASDAQ-SUPG)-Recommended 10/4/2010)
Buy Price-$2.31 (was $2.09 before adding $10,000)
Valuation $4.89 (was $4.37, $3.48)
Closed down $.33 at $2.83
SUPR announced last week that they were buying Astex, a UK company for $55 million in cash and stock. They will pay $25 million cash upfront and the remaining $30 million in cash or stock over 30 months. The deal is expected to close in July. The big, black mark on SUPG was that their drug pipeline was weak. From what we can tell, Astex is nothing but pipeline. They do not appear to have any commercial products and no close-in products, however, they have collaboration deals with a number of drug giants and have collected substantial milestone payments from them. There are $2 BILLION of potential milestone payments down the road. The combined company will have $120 million of cash, but we suspect the profitability will be gone. There is not enough public information at this point to update our valuation.
Upgraded to BUY by The Street.com recently.
Performance Technolgy (PTIX-Recommended 3/30/2010)
Valuation $3.79-(was $3.87, $5.03, $5.98, $7.13)
Closed down $.04 at $2.09
Last earnings report in March.Sales were down 18% from last year to $6.8 million, and they lost $2.8 million after adjusting out some one-time write-offs. Cash per share fell to $1.73, and our valuation fell to $3.79 as cash, sales and margins fell. They did say that Q1 2011 sales would be up 35-45% over Q4 and exceed any quarter in 2009 or 2010. We think we will hold on to this one a bit longer and see if they can get to a profit.
Down 23% HOLD
Extreme Networks (EXTR-Recommended 3/22/2010)
Buy Price-$3.18 (Was $3.04 before adding another $10,000)
Valuation-$7.36 (was $7.23, $7.31, $6.82, $6.81)
Closed down $.02 at $3.39
CFO resigned in March. Always makes stockholders jittery, but they also got a new CEO in October last year, so it is not unusual for a CFO to go, shortly after a new CEO comes in. They hired an interim CFO in March while they look for a permanent one.
Earnings out in February. Sales up 7% to $85 million and they made $.10 per share ($.06 if you exclude a favorable litigation settlement) versus a loss last year of $.02 per share. Cash per share rose $.08 to 1.55 and our valuation rose to $7.36. Next quarter guidance was $82-$85 million in sales and earnings of $.05-$.08 per share before a $.04/$.05 write off off some assets.
EXTR entered a settlement agreement with Ramius (Ramius owns 6.4% of EXTR). Declassify the Board, add a Ramius Director and the Ramius Director must be on any committee that reviews “strategic alternatives”. Pushing to sell EXTR obviously.
Still a cheap stock.
Up 7% HOLD
Broadvision (BVSN-Recommended 3/16/2010)
Valuation $22.95-(was $22.31, $21.77, $23.37, $27.15)
$13.87 per share in cash.
Closed down $.63 at $13.82.
Earnings out in January. Revenue was $5.1 million and they made $.01 per share. Cash per share fell a tad to $13.60. Our valuation inched up to $22.95.
Up 2%. HOLD
Ninetowns Internet Technology (NINE-Recommended 1/25/2010)
Valuation-$3.54 (Was $3.54, $3.19)
$2.88 per share in cash
Closed at $1.50, up $.10.
NINE announced last week they are going into the real estate business in China, by buying 141,000 sq. meters of land rights for $39 million (out of their $100 million or so). They plan to develop this land for mixed use residential and commercial. Have to wait on this one, as their grocery business was not doing much, but not sure we want to be in the real estate business.
Earning out in October. Sales were $5.67 million for the first 6 months of 2010 and they lost $1 million. Cash rose to $2.88 per share and our valuation stayed at $3.54. Only doing about $10 million a year in sales, but still trading way below (50%) cash value.
Down 2%. HOLD
Gravity Company Ltd. (GRVY-Recommended 1/18/2010)
Valuation $5.73-(Was $4.38, $4.44, $5.15)
Closed down $.17 at $1.82.
Earnings out in November. Not bad. Cash rose to $2.33 per share and they made $.08 per share. Our valuation jumped to $5.73. Not bad at all. New game coming out in Korea this quarter (War of Gods), although Ragnarok 2 is delayed until at least Q2 2011.
Up 8%. HOLD
AEterna Zentaris (AEZS-Recommended 6/20/2009)
Buy price $1.42 (was $1.78 before adding another $10,000, $1.82 before double up)
Closed down $.08 at $1.88.
Earnings out in March. Revenues about $10 million for the quarter and $27.7 for the year. They only lost $2.7 for the quarter and lost $20.5 for the year. Cash was $33.9 million before counting about $14 million of cash received in the current quarter for royalty payments, their Japan deal and sale of stock.
AEZS announced a new partnership for perifosine in Japan. They got $8 million upfront and up to another $60 million in the future. Plus AEZS gets to sell the compound to the company and gets double digit royalties. Not a bad deal.
Riding the tail of Kerx and perifosine, new orphan drug apporval from the FDA and a lot of investor interest in their pipeline of cancer products.
Speculative for sure.
Up 32% HOLD
Spectranetics (SPNC-Recommended 9/2/2006)
Buy price $5.68 (was $8.90, $9.40 before adding $10,000,and was $10.65 before double up), Valuation –$10.00
Closed up $.06 at $4.95.
SPNC got an approval in Japan last week to sell their lead locking device (used for removal of pacemaker and defibrillator leads). They also announced the start of a study on PAD (pheripheral arterial disease). It is expected to last about 6 months.
Hmmm, CFO and 2 other officers got “change of control” agreements in March. Hope they actually mean something!
SPNC announced earnings in February. Nothing to write home about. Sales decreased 1% to $29.3 million. At least they were able to earn a profit of $.02 a share-even after their million dollar charge for EG. I think the only way we are going to make money on this one is if they are sold. Otherwise they just can’t perform and I think the stock will go nowhere.
Good news. Geisemheimer is off the Board! Now just a consultant through June.
13D filed in November 2010. Paragon Assoc. disclosed a 2 million share (6%) ownership purchased at $5.16 per share. Maybe we have a catalyst finally to push management to do something (like sell this dog).
The company has $33 million in cash ($.99 per share), no debt and is growing about 5% a year. Teetering on a SELL here. Management is just terrible.
Down 13%. HOLD.
Mediware (MEDW-Recommended 6/4/2007)
Buy Price $6.33, (was $6.52, $6.67 ($10,000 added), $6.98 after double up)
Valuation $15.04 (was $14.23, $15.02, $14.35, $12.13, $12.57, $12.29, $11.90, $11.30, $11.48, $11.47 $10.99, $10.28, $13.32, $12.89, $13.40)
Closed down $.62 at $11.78
MEDW announced another acquisition in March. No details of what it cost, or what it will do to earnings.
Constellation continues to sell a few thousand shares here and there. Interesting move. Not sure if it is meant to goad MEDW management into doing something like selling the company to Constellation or someone else. The dollars involved in this sales is peanuts. It has been 9 months since they hired their investment bankers, so it is about time for something to happen, hopefully more than the acquisition last week.
Earnings out in February. Good again. Sales up 22% to $13.2 million and they made $.21 per share versus $.10 last year. Our valuation rose to $15.04–the highest ever.
MEDW re-engaged William Blair to look at “strategic alternatives”. Got to have an I Banker to sell your company.
Constellation now owns 21.8%.
All we read is that medical records will be a hot area, so MEDW looks like the place to be.
Up 86%. HOLD
Vertro. (VTRO (was-MIVA)-Recommended 10/21/2007)
Buy Price $8.15 (Was $11.90 before adding another $20,000, $13.10 before another $10,000 and was $15.00 before double up),
Valuation $14.23 (was $14.76, $12.40, $12.55, $10.85, $8.25, $9.45, $28.05, $32.10, $34.20, $37.90, $37.95)
Closed up $.02 at $3.56.
Earnings in March. As predicted they did $9.6 million in revenue and made $.11 a share from continuing operations. Our valuation fell to $14.37 and cash per share was $.88.
Down 56%. HOLD
Angeion Corporation. (ANGN-Recommended 8/28/2008)
Buy Price-$3.82 (was $5.15 before $10,000 added)
Valuation $13.60 (was $15.00, $13.06, $12.15, $11.29, $11.73, $11.47, $11.16, $9.53, $13.30, $13.03)
Closed down $.13 at $4.77
Earnings out in March. Not bad we thought. Sales up 7% to $7.1 million and they cut their weak quarter loss from $.20 a share to an adjusted profit of $.02 a share (excluding a severance charge for their ex-CEO). Our valuation fell to $13.60, but again this is their seasonally weak quarter, so we are not upset about it.
Up 25% BUY
OB-abies (Bulletin Board Listed Stocks)
As proven by OPTIO, patience is necessary with these stocks, especially in this Market.
ARI Networks (ARIS.ob-Recommended 8/19/2006)
Buy price $1.61 (Was $1.78 before another $10,000 added, was $2.06 before double up),
Valuation $5.39 (was $4,86, $5.60, $5.73, $5.54, $5.74, $5.96, $4.72, $5.19, $5.66, $5.63, $5.61, $5.71, $5.49, $5.34, $5.03, $5.28, $5.28, $5.21)
Closed at $.60 up $.03.
Earnings out in March. Sales down 2% to $5.238 million, operating income was $254,000 and they made $.02 per share. Our valuation jumped back up to $5.39 on higher than expected margins.
Wake up management–you have a great little company here worth 7X what it is selling for.
Now down 63%. BUY. Still a Huge valuation gap here.
Rand Worldwide (RWWI.ob (Was Avatech, AVSO.ob)-Bought November 28, 2005)
Buy price $.79 (Was $.93, $.99 and $1.19 before adding $10,000-each time),
Valuation $2.40 (was $1.90, $2.26 $3.07, $3.03, $2.38, $2.57, $2.81, $2.78, $3.30, $3.76, $4.00 $3.41, $3.05, $2.53, $3.25, $3.29 $2.69, $3.36, $3.81)
Stock closed at $.70, unchanged.
Earnings out in February. Sales were $21.7 million and they made $.02 a share. Our valuation jumped back up to $2.40 a share. Trading at 28% of our valuation. Cheap.
RWWI announced a $5.6 million deal in January. Maybe new management will get the word out on Rand and at least get us over $1.
Down 12%. BUY.
CTI Holdings (CTIG.ob-Recommended 2/25/2006)
Buy price $.27 ask,
Valuation $1.21 (Was $.71, $.83, $.88 $.96, $.93, $.75, $.85, $1.57, $1.40, $1.29, $1.38, $1.31, $1.38, $1.29, $1.42, $1.28 $1.13, $1.05, $.82)
Ask price $.09, closed at $.08.
Earnings out in March. Sales were $4.37 million and they actually made $200,000 of net income! Our valuation spiked back up to $1.21. They also announced that they signed a contract with a customer for $6 million most of which will come in Q2. Their VOIP business did $900,000 of revenue in 2010 compared to $150,000 in 2009.
At a $3 million market cap, this is stupidly cheap. Their itellectual property is probably worth 10 times this price. They need to liquify this value somehow.
They might have to sell or shut this VOIP business down in our opinion. Just losing too much money, and eroding shareholder value–or it could be a home run.
Still an “undercover” company and stock.
Down 67%. HOLD
Lotus Pharmaceuticals (LTUS.ob-Recommended 12/3/2007)
Buy price $1.68 (Was $1.80 before $10,000 adder, $2.16 before double-up)
Valuation-$4.11 (Was $4.84, $4.98, $4.60, $3.82, $4.00, $3.68, $3.12, $3.98, $4.44, $3.22, $2.12, $4.56, $4.16)
Closed at $.85, down $.20
This is the Rodney Dangerfield of stocks. No respect whatsoever. Now trading at close to one times this years earnings! Ghost stories of ALL Chinese reverse merger companies being shams continue to spook stockholders. We don’t think LTUS is one of them.
Earnings in March. Surprize, they wrote off $6.8 million of developement cost on the Mongolian property. Wham! Q4 sales were up 22% to $20 million. They made $.78 per share for the year after adjusting out the Mongolia write-off. Our valuation dropped to $4.11 per share on a slight drop in sales, lower income and more shares outstanding. Still a huge valuation gap.
Looks like the Mongolian land story has shifted again. Now they intend to keep some of the land and build a distribution facility on it and sell the rest for $50-$80 million-or enter into a developement deal to preserve about $6 million of tax benefits they are getting. The move into the Bejing building is delayed also–till sometime near the end of the year. This delay will keep 2011 sales and earning flat to slighly down. None of this impressed investors, and with a few other Chinese reverse merger stocks imploding due to CFO and auditor resignations here we are at $1.05 per share-25% of our valuation and less than a 1.5 PE. LTUS filed their 10k last week, with no auditor resignations! That alone should pust the stock back over $2.
When the Bejing building is complete, they expect to have invested a total of $48 million ($36 million already spent) and that based on current market values, the building will be worth over $100 million. This plus the Mongolian land are worth 3 times the current market cap of LTUS. Oh yeah, then there is the $.80 in annual earnings. Think this is a buy?
The stock split 2 for 1 in December. All of our numbers have been adjusted to reflect this split.
Down 50%. BUY